MIM
ORMP icon

MetLife Investment Management’s Oramed Pharmaceuticals ORMP Stock Holding History

MetLife Investment Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,360
Closed -$150K – 2895
2022
Q1 		$150K Buy
17,360
+6,407
+58% +$65.6K ﹤0.01% 2516
2021
Q4 		$156K Hold
10,953
– – ﹤0.01% 2207
2021
Q3 		$241K Hold
10,953
– – ﹤0.01% 1974
2021
Q2 		$147K Buy
+10,953
New +$125K ﹤0.01% 2337

Other funds holding ORMP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MetLife Investment Management's ORMP Position: Q2 2022 in Review

MetLife Investment Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2022, closing a stake of 17,360 shares — an estimated $150K sold.

MetLife Investment Management first reported a position in ORMP in Q2 2021 and held it in 4 quarters. The position peaked at $241K in Q3 2021. 88 funds tracked by Wall St. Rank hold ORMP as of Q2 2022.

  • MetLife Investment Management reported no remaining Oramed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • MetLife Investment Management sold 17,360 Oramed Pharmaceuticals shares in Q2 2022, an estimated $150K.
  • MetLife Investment Management first reported a position in Oramed Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • MetLife Investment Management's Oramed Pharmaceuticals position peaked at $241K in Q3 2021.
  • 88 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2022.

Based on MetLife Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.